AstraZeneca Reports Q3 Earnings Beat and Reaffirms FY2026 Guidance
AstraZeneca (AZN) reported third-quarter financial results exceeding market expectations, with Non-GAAP earnings per share reaching $2.79. The company's revenue climbed to $16.21 billion, representing a 6.7% year-over-year increase and beating estimates by approximately $210 million. Building on this momentum, AstraZeneca reaffirmed its long-term financial outlook for FY2026. The company expects total revenue to grow at a mid-to-high single-digit percentage rate while maintaining an upward trajectory for core earnings per share.
Tickers: $AZN
Topics: earnings beat financial guidance revenue growth
Read the full article at Seeking Alpha
Part of the story Capri Holdings Reports Q2 2027 Earnings Beat and Raises Full-Year Guidance (16 articles)